LXRX Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Lexicon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$2.47 |
| 52 Week Low | US$0.28 |
| Beta | 1.05 |
| 1 Month Change | -48.85% |
| 3 Month Change | -52.07% |
| 1 Year Change | -82.87% |
| 3 Year Change | -82.54% |
| 5 Year Change | -80.68% |
| Change since IPO | -99.72% |
Recent News & Updates
Recent updates
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Oct 16Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
May 28Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Mar 12Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Jan 26Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Shareholder Returns
| LXRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.5% | -2.4% | -0.2% |
| 1Y | -82.9% | -6.8% | 8.1% |
Return vs Industry: LXRX underperformed the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: LXRX underperformed the US Market which returned 8.1% over the past year.
Price Volatility
| LXRX volatility | |
|---|---|
| LXRX Average Weekly Movement | 22.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LXRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LXRX's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 103 | Mike Exton | www.lexpharma.com |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management.
Lexicon Pharmaceuticals, Inc. Fundamentals Summary
| LXRX fundamental statistics | |
|---|---|
| Market cap | US$131.29m |
| Earnings (TTM) | -US$200.40m |
| Revenue (TTM) | US$31.08m |
4.2x
P/S Ratio-0.7x
P/E RatioIs LXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXRX income statement (TTM) | |
|---|---|
| Revenue | US$31.08m |
| Cost of Revenue | US$84.00m |
| Gross Profit | -US$52.91m |
| Other Expenses | US$147.49m |
| Earnings | -US$200.40m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.55 |
| Gross Margin | -170.25% |
| Net Profit Margin | -644.78% |
| Debt/Equity Ratio | 68.7% |
How did LXRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 08:53 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lexicon Pharmaceuticals, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Kevin Kedra | G. Research, LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |